Title [*Name of your institution*]

*Die Bewerbung erfordert eine schriftliche Bestätigung durch die Leitung der Forschungseinrichtung über die Beteiligung der betreffenden Einrichtung bzw. die Bereitstellung der im Rahmen der Skizze dargestellten Infrastrukturkapazitäten als EU-OPENSCREEN Partnereinrichtung.*

Please use the following formatting:

|  |  |
| --- | --- |
| Font | Arial |
| Font Size | 10 |
| Line Spacing | 1.15 |
| Margins | 2 cm |

**Section 1 | Contact details, background information of the host institution and proposed partner site category**

max 1 page

Please provide contact details (names, addresses, email, phone and website links) for the:

* Legal representative of the host institution in which the proposed partner site would be embedded
* Main applicant representing the partner site (normally the principle investigator leading the efforts at the partner site)

Please provide background information on the host institution (legal entity) including:

* Date of founding; number of staff; and main research activities
* Position of the proposed partner site within the host institution (e.g. department or core facility within a university, working group within an applied research institute, platform group within a company etc.)

Please indicate the intended category of proposed partner site (see Technical and Scientific Description for details):

* Chemoproteomics site (this is the only valid category)

**Section 2 | Scientific excellence of the proposed partner site**

max 1 page, excluding CVs and publications

The following information should be provided:

* A description of the scientific profile and accomplishments of the proposed partner site including number of staff; relevant scientific or technological expertise; key research highlights and accomplishments. Please indicate how the research profile aligns with the intended category of partner site.
* The curriculum vitae of the main applicant and up to three additional personnel from the prospective partner site (up to 2 pages per person).
* A list of any additional publications, products, services (including widely used datasets or software), or other achievements of the partner site. Links to any online services (e.g. software tools) can also be included (no limit).

**Section 3 | Technical capabilities of the partner site and associated facilities at the host institution**

up to 2 pages

The applicant partner site will be approved as a “chemoproteomics partner site”, if it demonstrates that it has the instrumentation and expertise needed, and meets relevant criteria, for at least one of the above-mentioned areas. Depending on the area, in which a site has been evaluated, it will receive also additional 1 to 4 labels specifying which type of chemoproteomics expertise it provides, including:

1. Chemoproteomics partner site - Mass Spectrometry (MS)
2. Chemoproteomics partner site - Biochemical assays
3. Chemoproteomics partner site - Probe synthesis
4. Chemoproteomics partner site - Mass Spectrometry Imaging (MSI)

Please list major equipment available within the proposed partner site, e.g.:

* Mass spectrometry (MS) expertise and instrumentation for proteomic studies and data analysis, in particular:
	+ experimental design for chemoproteomics or compound disposition studies;
	+ sample preparation for chemoproteomics or compound disposition studies;
	+ LC-MS/MS (Liquid Chromatography-MS/MS) and other standard proteomics methods, including global approaches as well as targeted, quantitative methods for the analysis of proteins and their post-translational modifications by using label-free and label-based quantification strategies;
* Other advanced target identification methods, such as those based on cellular thermal shift assays (CETSA) and isothermal dose response (ITDR) experiments;
* Design, synthesis and purification of chemical probes with linkers allowing for the pull-down of the target(s) or similar target identification approaches (the partner site should have experience in linker chemistry and ligand-linker synthesis);
* Advanced mass spectrometry imaging (MSI) instrumentation for the quantification of compound disposition in tissues and cell models, together with analysis workflows for quantification and interpretation of MSI readouts

Please list associated support / core facilities within the host or affiliated institutions which could also be utilised by the partner site for EU-OPENSCREEN ERIC projects, e.g.:

* Core facilities for cell line generation, QC etc.
* Core facilities for protein expression and purification
* Core groups providing large-scale sequencing, proteomics services etc.
* Centralised chemistry analytics (e.g. NMR)
* Collections of chemical intermediates, -building blocks and –scaffolds

Please list chem- / bioinformatics resources and briefly outline how these are used in data handling processes within the proposed partner site, e.g.:

* Informatics data analysis tools (in-house and / or commercial)
* Bioinformatics software tools / resources
* Cheminformatics software tools / resources
* In silico screening and rational drug discovery tools
* Data processing and bioinformatics pipelines, including statistical analysis;
* Data interpretation and expertise on deposition of FAIR omics-results onto community data repositories;
* Associated core facilities or informatics infrastructures, which could be utilised for EU-OPENSCREEN ERIC projects (e.g. distributed- and / or super-computing facilities, access to software development teams etc.)

**Section 4 | Achievements and existing capacity to provide services, including track record in project execution**

up to 2 pages

Please summarise projects supported by the proposed partner site in the last six years (2017 - 2022):

* Give total number of chemoproteomics and compound disposition projects performed
* List technologies used

Describe, in brief, three representative projects from the last six years, which are relevant to your intended partner site category. For each project, please include information on:

* Project scope
* Scientific and technical features (e.g. target class or cellular pathway investigated, disease indication, types of assays developed, technologies and techniques used, etc.)
* Key outcomes (e.g. scientific peer-reviewed publications and patents granted, students trained, targets identified or validated, tool compounds / leads declared, companies spun out, novel chemistry developed. software released etc.)

**Section 5 | Future capacity for user projects and sustainability**

max 0.5 page

Capacity of proposed partner site to meet future needs of EU-OPENSCREEN ERIC users. For the following five years, please estimate the annual number of slots that will be available to EU-OPENSCREEN ERIC users for:

* Chemoproteomics and compound disposition projects

Outline the sustainability plan for the proposed partner site for the long term (>five years). Describe how the provisions within the sustainability plan would provide a secure basis for continued membership of the EU-OPENSCREEN ERIC in the long term.

**Section 6 | Added value for the EU-OPENSCREEN ERIC and alignment with the EU-OPENSCREEN ERIC policies**

max 0.5 page

Prospective partner sites should briefly describe how their participation in the EU-OPENSCREEN ERIC would provide added value to the users and the network. Specific examples may involve:

* Providing complementary or unique technologies and expertise
* Introducing appropriate QC processes and standardisation in methodology which helps improve data reproducibility in early stage research
* Providing broad access to advanced assay protocols, high quality reagents, novel software tools etc.

**Appendix**

CV of the principle investigator (up to 2 pages)

CV of up to three additional personnel (up to 2 pages each)

A list of any additional publications, products, services (no limit)